Loading...
XNYS
DNA
Market cap442mUSD
Aug 24, Last price  
6.78USD
1D
6.32%
1Q
-12.01%
IPO
-98.18%
Name

Ginkgo Bioworks Holdings Inc

Chart & performance

D1W1MN
XNYS:DNA chart
P/E
P/S
2.60
EPS
Div yield, %
Shrs. gr., 5y
11.72%
Rev. gr., 5y
17.29%
Revenues
170m
-25.06%
98,285,00054,184,00076,657,000313,837,000477,706,000251,455,000227,043,000170,155,000
Net income
-313m
L-42.83%
0-119,327,000-126,609,000-1,830,047,000-2,104,929,000-892,869,000-547,029,000-312,763,000
CFO
-171m
L-46.47%
-145,917,000-44,663,000-135,830,000-253,818,000-252,198,000-295,500,000-319,585,000-171,059,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
IPO date
Apr 19, 2021
Employees
1,292
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT